Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Peptide-Centric CAR Construction Service

Online Inquiry

Background Advantage Service What We Can Offer Highlights FAQs Related Services Published data

The Importance of Peptide-centric CAR

Despite having obvious therapeutic effects on leukemias, the limited availability of tumor-specific membrane proteins for solid tumor killing limits CAR-T cell therapy. The Peptide-Centric Chimeric Antigen Receptor (PC-CAR) is a novel type of CAR that can detect oncoprotein epitopes displayed on the cell surface by HLAs. Scientists have developed a PC-CAR that targets the neuroblastoma-associated PHOX2B peptide. This makes it easier to kill tumor cells that share two common HLA allotypes. Therefore, peptide-centric CAR construction exhibits a promising strategy to expand CAR-T cell therapy for solid tumors and other types of cancer.

Fig. 1 PC-CARs targeting neuroblastoma's oncogenic peptide.¹

Key Advantages of PC-CAR for Targeting MHC Peptides Compared to TCR

Wider targeting scope: PC-CAR can effectively target mutated oncoproteins.
Superior peptide selectivity: PC-CAR can be characterized by superior peptide selectivity owing to its freedom from germline-encoded CDR1 and CDR2 constraints.
Expander clinical research: Based on the second point, PC-CAR can target a peptide presented by multiple HLA alleles.

Our Peptide-centric CAR Construction Services: Comprehensive! Fast! Excellent!

Creative Biolabs has developed and widely provides peptide-centric CAR construction services for global customers to aid in your drug development projects. We can design specific PC-CARs targeting tumor-associated proteins according to the diverse needs of customers. Specifically, we provide well-developed several platforms for global customers to screen the appropriate scFv and can customize our service if you have desirable targets. In addition, we also deliver other types of CAR construction services (Leucine Zipper (SUPRA) CAR, Anti-FITC CAR, Convertible CAR, etc.) to support your projects. At Creative Biolabs, we provide full-around peptide-centric CAR construction services ranging from design to evaluation to enable your projects to run smoothly.

Fig. 2 Workflow of CAR construction services.

What We Can Offer

Our PC-CAR Construction Service leverages a portfolio of advanced technology platforms to accelerate the development of highly specific and effective immunotherapies. We provide comprehensive support from target discovery to functional validation.

Our comprehensive service workflow is meticulously designed to move your universal CAR candidate from concept to preclinical validation efficiently and reliably.

Target Discovery and Design	Genetic delivery and production platforms
Immunopeptidomics High-throughput peptide screening Computational modeling and structural docking	Lentiviral/retroviral vectors Non-viral methods Generate peptide-expressing CAR cells
Peptide-to-CAR integration	In vitro functional assays
Modular extracellular domain design Multivalent / tandem peptide repeats Peptide + scaffold fusion Logic & switchable formats	Binding and affinity characterization Cytotoxicity assays Cytokine profiling and polyfunctionality Activation and exhaustion markers Serial killing, persistence & proliferation assays
In vivo models & safety	Analytics and QC
Xenograft models Humanized models On-target/off-tumor toxicity screens Biodistribution & persistence assays	Sequence verification Cell product QC Peptide characterization Manufacturing readiness

Kindly get in touch with our team to address your individual requirements in detail.

Our Advantage

Integrated Workflow: The entire process (from gene synthesis to vector assembly) is governed by a robust quality system to ensure consistency and reliability.
Advanced Vector Production: We have infrastructure for large-scale, high-titer lentiviral vector manufacturing, enabling rapid transition from discovery to pre-clinical and early clinical phases.
Guaranteed Receptor Stability & Function: Stringent quality assessment of scFv components and vector designs ensures the constructed CARs' stability and functional persistence in T-cell banks and during large-scale cell processing.

FAQs

How does Peptide-Centric CAR construction overcome the safety and targeting limitations of traditional CAR-T therapies that target surface antigens?

Traditional CAR-T is restricted to targets found exclusively on the cell surface. Our Peptide-Centric approach allows you to access the vast, hidden intracellular proteome by targeting highly specific peptides presented on the pMHC. This strategy provides access to novel, tumor-specific antigens derived from intracellular oncogenic proteins, dramatically increasing target specificity.

We have a proprietary tumor cell line with a specific, rare MHC-I haplotype. Can your service handle highly customized or non-standard pMHC target identification?

Absolutely. Customization is the foundation of our service. Creative Biolabs does not rely on generic targets. Our robust, integrated Immunopeptidome Analysis platform is designed to isolate, sequence, and validate peptide epitopes from your specific tumor samples, cell lines, or patient-derived xenografts (PDX).

Related Services

Switchable CAR Construction

Creative Biolabs' CellRapeutics™ Switchable CAR Construction Service empowers precise, controllable immunotherapy design - offering customizable, drug- or adaptor-responsive CAR systems to enhance safety, flexibility, and therapeutic performance across diverse cell therapy applications.

Soluble Ligand-sensing CAR Construction

CellRapeutics™ Soluble Ligand-sensing CAR Construction Service enables the creation of CARs that detect and respond to soluble cues, providing tunable control over immune activation for enhanced therapeutic precision and reduced off-target toxicity.

Synthetic Intramembrane Proteolysis Receptor CAR Construction

CellRapeutics™ Synthetic Intramembrane Proteolysis Receptor CAR Construction Service delivers advanced receptor designs utilizing intramembrane proteolysis signaling to achieve precise, signal-dependent immune modulation and next-generation control of CAR cell activation.

Representative Data

The unmutated peptide QYNPIRTTF, which is expressed on HLA-A*24:02, piqued the researchers' curiosity. This peptide is derived from PHOX2B, a neuroblastoma-dependent gene and master transcriptional regulator. Using anticipated possibly cross-reactive peptides, researchers developed peptide-centered chimeric antigen receptors (PC-CARs) by a strategy known as "counter-panning." These results suggest that PC-CARs might be able to add non-immunogenic intracellular oncoproteins to the list of immunotherapy targets. This means that additional HLA isotypes might be exploited for therapeutic targeting.

Our peptide-centric CAR construction services are available for multiple cell types:

Cell line
Primary cell

We provide rapid and robust virus transduction systems, including both plasmid products and also viral products, to aid in our peptide-centric CAR construction services:

Retrovirus transduction system
Lentiviral transduction system

In addition, we also provide full-process function validation (in vitro and in vivo) to evaluate the PC-CAR:

The detection of PC-CAR surface expression;
The examination of engineered T cells in antigen recognizing and killing;
The production of cytokines;
The identification of stability.

Fig. 3 Tumor killing and breakthrough induced by PHOX2B-specific PC-CAR T cells. (Yarmarkovich, et al., 2021) Fig.3 Tumor killing and breakthrough induced by PHOX2B-specific PC-CAR T cells.²

As a leader in immunotherapy development, Creative Biolabs strives to provide CAR construction services to aid in drug development for cancer therapy. If you are interested in our peptide-centric CAR construction services, please contact us for more details at your convenience.

References

Irving, Melita, et al. "A roadmap for driving CAR T cells toward the oncogenic immunopeptidome." Cancer Cell 40.1 (2022): 20-22.
Yarmarkovich, Mark, et al. "Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs." Nature 599.7885 (2021): 477-484.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.